Nelarabine in Adult Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia/Lymphoma(T-ALL/T-LBL): The Mayo Clinic Experience

Abstract

First line treatment strategies for adults with T-ALL/T-LBL are suboptimal, with over 50% of patients relapsing. Long term survival in the relapsed and refractory setting is ∼10%. The goal of salvage therapy is to achieve a durable response as a bridge to stem cell transplant (HCT). Nelarabine, a purine nucleoside analog, has been used for salvage therapy with reasonable success.